Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genovis AB (GENO.ST)
Kävlinge, SE
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.50% | -1.70% | +4.12% | +16.76% | +0.00% | -7.13% | -22.46% | -61.15% | -51.21% | +1,283.56% | -58.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-1.1% Q1'26: +3.8% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-28.0% Q1'26: +13.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+15.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+21.3% ★ Q1'26: +17.2% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+9.7% ★ Q1'26: +9.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.5% Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×3.52× ★ Q1'26: 2.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.27M
est: 14.06M (-5.6%)
|
18.54M
est: 18.00M (+3.0%)
|
22.87M
est: 22.63M (+1.0%)
|
34.57M
est: 34.00M (+1.7%)
|
60.55M
est: 62.00M (-2.3%)
|
61.03M
est: 58.70M (+4.0%)
|
93.02M
est: 123.00M (-24.4%)
|
102.39M
est: 106.00M (-3.4%)
|
158.23M
est: 127.86M (+23.8%)
|
130.36M
est: 142.75M (-8.7%)
|
128.95M
est: 126.23M (+2.2%)
|
144.83M
138.58M – 152.28M
+14.7% YoY
|
182.60M
169.74M – 202.19M
+26.1% YoY
|
223.03M
220.34M – 225.71M
+22.1% YoY
|
248.00M
233.54M – 268.47M
+11.2% YoY
|
286.00M
269.32M – 309.61M
+15.3% YoY
|
| EBITDA |
-18.51M
est: 4.08M (-554.0%)
|
-13.48M
est: 5.22M (-358.2%)
|
-6.23M
est: 6.56M (-194.9%)
|
2.08M
est: 9.86M (-78.9%)
|
17.02M
est: 17.98M (-5.3%)
|
8.57M
est: 17.02M (-49.6%)
|
28.88M
est: 35.67M (-19.0%)
|
14.91M
est: 30.74M (-51.5%)
|
66.84M
est: 41.37M (+61.6%)
|
56.18M
est: 46.19M (+21.6%)
|
39.77M
est: 40.84M (-2.6%)
|
46.86M
44.84M – 49.27M
+14.7% YoY
|
59.08M
54.92M – 65.42M
+26.1% YoY
|
72.16M
71.29M – 73.03M
+22.1% YoY
|
80.24M
75.56M – 86.87M
+11.2% YoY
|
92.54M
87.14M – 100.18M
+15.3% YoY
|
| EBIT |
-19.82M
est: 3.07M (-745.5%)
|
-14.77M
est: 3.93M (-475.5%)
|
-7.84M
est: 4.95M (-258.4%)
|
-960.6K
est: 7.43M (-112.9%)
|
10.07M
est: 13.55M (-25.7%)
|
4.28M
est: 12.83M (-66.6%)
|
23.11M
est: 26.88M (-14.0%)
|
8.28M
est: 23.16M (-64.3%)
|
57.11M
est: 32.07M (+78.1%)
|
45.73M
est: 35.81M (+27.7%)
|
27.49M
est: 31.66M (-13.2%)
|
36.33M
34.76M – 38.20M
+14.7% YoY
|
45.80M
42.58M – 50.72M
+26.1% YoY
|
55.95M
55.27M – 56.62M
+22.1% YoY
|
62.21M
58.58M – 67.35M
+11.2% YoY
|
71.74M
67.56M – 77.66M
+15.3% YoY
|
| Net Income |
-19.91M
est: -30.16M (+34.0%)
|
-15.03M
est: -17.02M (+11.7%)
|
-7.95M
est: -7.90M (-0.6%)
|
-1.71M
est: -3.27M (+47.7%)
|
9.55M
est: 11.78M (-18.9%)
|
6.45M
|
24.78M
est: 42.55M (-41.8%)
|
11.19M
est: 28.10M (-60.2%)
|
61.50M
est: 17.25M (+256.5%)
|
32.92M
est: 26.96M (+22.1%)
|
23.50M
est: 20.71M (+13.4%)
|
26.50M
19.15M – 30.89M
+27.9% YoY
|
40.27M
31.84M – 45.49M
+51.9% YoY
|
56.27M
46.01M – 65.18M
+39.7% YoY
|
63.15M
58.36M – 69.93M
+12.2% YoY
|
78.28M
72.35M – 86.68M
+24.0% YoY
|
| SGA |
21.49M
est: 6.59M (+225.9%)
|
26.01M
est: 8.45M (+207.9%)
|
14.63M
est: 10.62M (+37.8%)
|
13.58M
est: 15.95M (-14.9%)
|
17.00M
est: 29.09M (-41.6%)
|
18.66M
est: 27.54M (-32.3%)
|
21.97M
est: 57.71M (-61.9%)
|
68.19M
est: 49.73M (+37.1%)
|
88.20M
est: 52.17M (+69.1%)
|
75.69M
est: 58.25M (+29.9%)
|
—
est: 51.51M (-100.0%)
|
59.10M
56.55M – 62.14M
+14.7% YoY
|
74.51M
69.26M – 82.50M
+26.1% YoY
|
91.00M
89.91M – 92.10M
+22.1% YoY
|
101.20M
95.29M – 109.55M
+11.2% YoY
|
116.70M
109.90M – 126.33M
+15.3% YoY
|
| EPS |
-0.66
est: -0.46 (-43.3%)
|
-0.32
est: -0.26 (-23.1%)
|
-0.14
est: -0.12 (-16.0%)
|
-0.03
est: -0.05 (+44.8%)
|
0.15
est: 0.18 (-16.7%)
|
0.10
|
0.38
est: 0.65 (-41.5%)
|
0.17
est: 0.43 (-60.5%)
|
0.94
est: 0.26 (+256.8%)
|
0.50
est: 0.40 (+26.6%)
|
0.36
est: 0.31 (+16.1%)
|
0.39
0.29 – 0.47
+24.2% YoY
|
0.61
0.48 – 0.69
+59.1% YoY
|
0.82
0.70 – 0.99
+34.3% YoY
|
0.96
0.89 – 1.06
+16.7% YoY
|
1.19
1.10 – 1.32
+24.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fredrik Olsson | President & Chief Executive Officer | — | male |
| John Lindsay | President of Genovis Inc. | — | male |
| Magnus Langberg | Group Chief Financial Officer | — | male |
| Maria Edholm | Controller | — | female |
| Rikke Rytter | Vice President of Sales & Marketing | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GENO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
